Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Advanced Endometrial Cancer
Interventions
DRUG

EG-007

A Repurposed Drug

DRUG

Pembrolizumab 100 mg/4 mL (25 mg/ml) Injection

Pembrolizumab will be provided as a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution that requires dilution for intravenous infusion. Each vial contains 100 mg of pembrolizumab in 4 mL of solution.

DRUG

Lenvatinib Capsules

Lenvatinib will be provided as 4-mg and 10-mg capsules. Lenvatinib is formulated with calcium carbonate, mannitol, microcrystalline cellulose, hydroxypropyl cellulose, low-substituted hydroxypropylcellulose, and talc.

Sponsors
All Listed Sponsors
lead

Evergreen Therapeutics, Inc.

INDUSTRY